EQ Projected Dividend Yield
Equillium Inc ( NASDAQ : EQ )Equillium is a clinical-stage biotechnology company to develop therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Co.'s pipeline is focused on developing itolizumab (EQ001), EQ101 and EQ102 as potential disease modifying treatments for multiple severe immuno-inflammatory disorders. Co. has active clinical development programs for itolizumab (EQ001) for the treatment of acute graft-versus-host disease and lupus/lupus nephritis. Co. also has a proprietary product discovery platform that it can utilize to design peptides to target and inhibit multiple cytokines that are involved in validated biological and disease pathways. 20 YEAR PERFORMANCE RESULTS |
EQ Dividend History Detail EQ Dividend News EQ Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |